Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

COLCOVID
 
NCT04328480
RCTcolchicinestandard of careCOVID 19 hospitalizedsome concern
640/639 inconclusive
  • inconclusive 17 % decrease in death or ventilation (PE) with a moderate degree of certainty due to some concern in risk of bias
Horby
 
NCT04381936
RCTcolchicinestandard of careCOVID 19 hospitalizedsome concern
5610/5730 inconclusive
    Lanzoni
     
    NCT04355728
    RCTstem cellsplaceboCOVID 19 hospitalizedsome concern
    12/12 suggested
    • suggested 86 % decrease in death D28 with a moderate degree of certainty due to some concern in risk of bias
    • suggested 89 % decrease in deaths,deaths (time to event analysis only) with a moderate degree of certainty due to some concern in risk of bias
    RECOVERY (colchicine)
     
    NCT04381936
    RCTcolchicinestandard of careCOVID 19 hospitalizedsome concern
    5610/5730 inconclusive
    • inconclusive 1 % increase in deaths,death D28 (PE) with a moderate degree of certainty due to some concern in risk of bias
    GRECCO-19
     
    NCT04326790
    RCTcolchicinestandard of careCOVID 19 hospitalizedsome concern
    55/50 suggested
    • suggested 89 % decrease in clinical deterioration (PE) with a moderate degree of certainty due to some concern in risk of bias
    Salehzadeh
     
    IRCT20200418047126N1
    RCTcolchicineplaceboCOVID 19 hospitalizedsome concern
    50/50 inconclusive
      Comparing two groups showed significantly different only in the duration of hospitalized (P<0.05). Although in colchicine group dyspnea was improved more rapid than the placebo group, but it was not meaningful.

      COVID-19 mild to moderate meta-analysis

      COL-COVID (Pascual-Figal)
       
      NCT04350320
      RCTcolchicinestandard of careCOVID-19 mild to moderatesome concern
      52/51 inconclusive
        Rashad (CLARI vs SoC) RCTclarithromycinestandard of careCOVID-19 mild to moderatesome concern
        99/99 suggested
        • suggested 1.9-fold increase in radiologic improvement (14-day) with a moderate degree of certainty due to some concern in risk of bias

        COVID-19 severe or critically meta-analysis

        Shi
         
        NCT04288102
        RCTstem cellsplaceboCOVID-19 severe or criticallysome concern
        66/35 inconclusive
          Shu
           
          ChiCTR2000031494
          RCTstem cellsstandard of careCOVID-19 severe or criticallysome concern
          12/29 suggested
          • inconclusive 73 % decrease in clinical deterioration (PE) with a moderate degree of certainty due to some concern in risk of bias
          • suggested 9.3-fold increase in clinical improvement,clinical improvement (14-day) with a moderate degree of certainty due to some concern in risk of bias
          • suggested 5.7-fold increase in clinical improvement (7-day) with a moderate degree of certainty due to some concern in risk of bias
          10 studies excluded by filtering options (2 RCT / 8 OBS)

          PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
          Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).